Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell-mediated immunosuppression and potentiates anti-PD-1 therapy in ovarian cancer.
Dong S, Ye C, Li B, Lv F, Zhang L, Yang S, Wang F, Zhu M, Zhou M, Guo F, Li Z, Peng L, Ji C, Lu X, Cheng Y, Ren X, Chen Y, Zhou J, Yang J, Zhang Y.
Dong S, et al. Among authors: ji c.
Cancer Immunol Res. 2024 Nov 12. doi: 10.1158/2326-6066.CIR-24-0084. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 39531476